Trials
Search / Trial NCT06438874

Type 2 Diabetes Post Exercise Arterial Stiffness

Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · May 29, 2024

Apply for Trial

Trial Information

Current as of March 12, 2025

Not yet recruiting

Keywords

ClinConnect Summary

Type 2 diabetes mellitus (T2DM) is a significant public health concern associated with increased cardiovascular morbidity and mortality. Notably, individuals with T2DM often exhibit increased arterial stiffness, a key indicator of cardiovascular risk. Pharmacological interventions such as GLP1 agonists have emerged as crucial treatments for T2DM, offering glycemic control and potential cardiovascular benefits, including improvements in blood pressure and arterial stiffness. However, while the effects of GLP1 agonists on glycemic control and blood pressure regulation have been explored, thei...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Individuals diagnosed with type 2 diabetes mellitus (T2DM).
  • • Age between 18 and 60 years old.
  • • Currently receiving treatment with a glucagon-like peptide 1 (GLP1) agonist for the management of T2DM for a minimum duration of six months.
  • • For control group no current use of a glucagon-like peptide 1 (GLP1) agonist for the management of type 2 diabetes mellitus (T2DM).
  • • HbA1c levels between 6.5-8%
  • • Body Mass Index (BMI) within the range of 25 to 40 kg/m2.
  • Exclusion Criteria:
  • • Coronary heart disease.
  • • Pulmonary disease (e.g. asthma, chronic obstructive pulmonary disease)
  • • Neurological disorders (e.g. Alzheimer's disease, dementia)
  • • Congestive heart failure.
  • • Peripheral vascular disease.
  • • Liver failure.
  • • Kidney failure.
  • • Alcohol abuse.
  • • Drug abuse.
  • • Smoking.
  • • Hypertension (defined as Systolic Blood Pressure ≥ 140 mmHg or Diastolic Blood Pressure ≥ 90 mmHg)
  • • Insulin therapy for the management of T2DM
  • • Severe obesity (defined as Body Mass Index \>40 kg/m2);
  • • Pregnancy
  • • Non-English speaking individuals

Trial Officials

Ronald E Jackson, PhD

Principal Investigator

University of Illinois Chicago

About University Of Illinois At Chicago

The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0